Bausch Health Companies (NYSE:BHC) Now Covered by Analysts at Raymond James

Raymond James started coverage on shares of Bausch Health Companies (NYSE:BHCFree Report) in a report released on Wednesday, MarketBeat.com reports. The firm issued a market perform rating and a $8.00 target price on the stock.

Several other equities research analysts have also commented on BHC. StockNews.com upgraded shares of Bausch Health Companies from a hold rating to a buy rating in a research note on Wednesday, May 15th. Royal Bank of Canada dropped their price target on shares of Bausch Health Companies from $12.00 to $11.00 and set a sector perform rating on the stock in a research note on Tuesday, April 23rd. Finally, Piper Sandler raised their price target on shares of Bausch Health Companies from $7.00 to $9.00 and gave the company a neutral rating in a research note on Monday, April 29th. Three analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of Hold and an average price target of $10.50.

Check Out Our Latest Research Report on Bausch Health Companies

Bausch Health Companies Stock Up 1.9 %

BHC opened at $7.33 on Wednesday. The firm has a market cap of $2.64 billion, a price-to-earnings ratio of -5.91 and a beta of 0.77. Bausch Health Companies has a fifty-two week low of $6.05 and a fifty-two week high of $11.46. The company’s 50-day moving average price is $6.76 and its 200 day moving average price is $8.08.

Bausch Health Companies (NYSE:BHCGet Free Report) last released its quarterly earnings data on Thursday, May 2nd. The company reported $0.59 earnings per share for the quarter, missing the consensus estimate of $0.75 by ($0.16). The business had revenue of $2.15 billion for the quarter, compared to analyst estimates of $2.18 billion. Bausch Health Companies had a negative return on equity of 2,370.91% and a negative net margin of 5.07%. Research analysts anticipate that Bausch Health Companies will post 3.63 earnings per share for the current year.

Institutional Investors Weigh In On Bausch Health Companies

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in BHC. Salem Investment Counselors Inc. acquired a new stake in shares of Bausch Health Companies in the 1st quarter valued at $32,000. CANADA LIFE ASSURANCE Co lifted its stake in shares of Bausch Health Companies by 4.1% in the 1st quarter. CANADA LIFE ASSURANCE Co now owns 88,457 shares of the company’s stock valued at $933,000 after purchasing an additional 3,519 shares during the last quarter. Principal Securities Inc. acquired a new stake in shares of Bausch Health Companies in the 4th quarter valued at $31,000. Blair William & Co. IL lifted its stake in shares of Bausch Health Companies by 5.0% in the 1st quarter. Blair William & Co. IL now owns 84,245 shares of the company’s stock valued at $894,000 after purchasing an additional 4,000 shares during the last quarter. Finally, Pinnacle Associates Ltd. lifted its stake in shares of Bausch Health Companies by 14.1% in the 1st quarter. Pinnacle Associates Ltd. now owns 33,649 shares of the company’s stock valued at $357,000 after purchasing an additional 4,149 shares during the last quarter. Hedge funds and other institutional investors own 78.65% of the company’s stock.

About Bausch Health Companies

(Get Free Report)

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.

See Also

Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.